4-methyl-3-(1'H-indol-3'-yl)maleimide | 870556-27-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-methyl-3-(1'H-indol-3'-yl)maleimide
• 英文别名: 3-(1H-indol-3-yl)-4-methylpyrrole-2,5-dione
• CAS: 870556-27-7
• 化学式: C₁₃H₁₀N₂O₂
• 分子量: 226.235
• InChiKey: NMSJDSHYKGIIIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  62
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1,4,7,10-tetraazacyclododecane)Zn(II) perchlorate monohydrate 、 4-methyl-3-(1'H-indol-3'-yl)maleimide 在 三乙胺 作用下， 以 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Asymmetric Indolylmaleimide Derivatives and Their Complexation with Zinc(II)−Cyclen

  摘要：

  The spectroscopic properties of two asymmetric indolylmaleimide derivatives, 4-bromo-3-(1'H-indol-3'-yl)-maleimide and 4-methyl-3-(1'H-indol-3'-yl)maleimide, are investigated. The bromo derivative was crystallized and its X-ray structure was determined. Both compounds are strongly colored while their separate components (indole and maleimide) absorb in the UV region only. To understand the ground- and excited-state behavior, the photophysical properties of the two compounds were studied in detail by steady state and time-resolved absorption and emission spectroscopy. Their solvatochromic behavior was investigated by using the Kamlet-Taft approach, which indicates some charge transfer (CT) character in the excited state. Nano- and femtosecond transient absorption spectroscopy was used for the identification and investigation of the CT state. Furthermore, the effect of the complexation with zinc(II) 1,4,7, 11-tetraazacyclododecane (Zn-cyclen) on the photophysical properties of these two compounds was studied. An enhancement of the fluorescence intensity upon self-assembly (up to 90 times) and high association constants were observed, which illustrate the potential use of these compounds as luminescent sensors. DFT calculations indicate that HOMO-1 to LUMO excitation is mainly responsible for the charge transfer character and that this transition changes its character drastically when Zn-cyclen complexation occurs, thus giving it sensor properties.

  DOI：

  10.1021/jp054651z

文献信息

• PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JA K3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS
  申请人：Maibucher Axel

  公开号：US20090062301A1

  公开（公告）日：2009-03-05

  The present invention relates to a pharmaceutical combination comprising at least one PKC inhibitor, in particular indolylmaleimide derivatives, and at least one JAK3 kinase inhibitor and the uses of such a combination e.g. in autoimmune diseases, e.g. in preventing or treating type I diabetes mellitus and disorders associated therewith, or in transplantation.